Surmodics, Inc. SRDX is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter ...
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial ...
On May 29, 2024, Surmodics announced it had entered into a definitive merger agreement to be acquired by funds affiliated with GTCR, a leading private equity firm with a long track record of ...
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that third quarter ...
Surmodics, Inc. (Nasdaq: SRDX) (“Surmodics” or the “Company”), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it expects to ...
) announced after the market closed on Wednesday that it missed consensus Wall Street estimates. SurModics, Inc reported a 4th quarter net loss of $21.7 million, or $1.25 per share, compared to net ...
Surmodics, Inc. SRDX is well poised for growth backed by In Vitro Diagnostics (IVD) unit’s consistent growth and persistent efforts to bolster research and development (R&D) functionalities. The stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results